BDX BCAL Diagnostics Limited
Healthcare · Diagnostics & Research
· website
$0.09
52wk 0.05 – 0.15
Overall
26.8
Value
72.7
Growth
0.0
Health
16.4
Quality
0.0
Momentum
41.9
Dividend
—
Price
About BCAL Diagnostics Limited
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Price analytics
Returns
| 1 day | -3.3% |
| 1 week | 7.4% |
| 1 month | 26.1% |
| 3 months | 20.8% |
| 6 months | -3.3% |
| 1 year | 17.6% |
| 3 years | -11.2% |
Risk
| Volatility (1y ann.) | 96.4% |
| Beta vs ASX 200 | 0.00 |
| Sharpe (1y) | 0.56 |
| VaR 95% (1-day) | -7.2% |
| Max drawdown (1y) | -61.5% |
| Off 1-year high | -35.6% |
Technicals
| RSI(14) | 67 |
| vs 50DMA | 25.1% |
| vs 200DMA | -1.4% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
72.7
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
100
Price / Sales
0
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
16.4
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
33
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
41.9
6-month return vs ASX 200
6
Price vs 200-day average
45
Price vs 50-day average
100
Position in 52-week range
34
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$32.08M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.02
Dividend yield
—
Payout ratio
0.0%
Beta
0.81
EV / EBITDA
-5.68
Price / Book
-43.50
ROE
-273.3%
Operating margin
-313.4%
Net margin
0.0%
Total cash
$1.59M
Total debt
$6.92M
Current ratio
1.36
Debt / Equity
—
Free cash flow
$-3.96M
Avg volume
116,534
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$21.64K
- Gross profit$21.64K
- Operating income-$9.96M
- Net income-$7.24M
- Diluted EPS-0.02
- Free cash flow-$6.92M
- Net debt-$2.14M